We Think You Can Look Beyond Shenzhen Neptunus Interlong Bio-technique's (HKG:8329) Lackluster Earnings
We Think You Can Look Beyond Shenzhen Neptunus Interlong Bio-technique's (HKG:8329) Lackluster Earnings
The market for Shenzhen Neptunus Interlong Bio-technique Company Limited's (HKG:8329) shares didn't move much after it posted weak earnings recently. We think that the softer headline numbers might be getting counterbalanced by some positive underlying factors.
深圳海王英特隆生物技术有限公司(HKG: 8329)在最近公布疲软的收益后,其股票市场没有太大波动。我们认为,较疲软的标题数字可能会被一些积极的潜在因素所抵消。
![earnings-and-revenue-history](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240419/0-a5be11d37ff8dd85f5cef4a46bafb34c-0-9486c976dd004f1951ba1f10b81342f9.png/big)
The Impact Of Unusual Items On Profit
不寻常物品对利润的影响
To properly understand Shenzhen Neptunus Interlong Bio-technique's profit results, we need to consider the CN¥18m expense attributed to unusual items. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual expenses don't come up again, we'd therefore expect Shenzhen Neptunus Interlong Bio-technique to produce a higher profit next year, all else being equal.
为了正确了解深圳海王英特隆生物技术的利润业绩,我们需要考虑归因于不寻常项目的1800万元人民币支出。尽管由于不寻常项目而产生的扣除首先令人失望,但有一线希望。当我们分析全球绝大多数上市公司时,我们发现重大不寻常的事项往往不会重演。而且,毕竟,这正是会计术语的含义。假设这些不寻常的支出不会再次出现,因此,我们预计深圳海王星英特隆生物技术在其他条件相同的情况下,明年将产生更高的利润。
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Shenzhen Neptunus Interlong Bio-technique.
注意:我们始终建议投资者检查资产负债表的实力。点击此处查看我们对深圳海王星英特隆生物技术的资产负债表分析。
Our Take On Shenzhen Neptunus Interlong Bio-technique's Profit Performance
我们对深圳海王英特隆生物科技盈利表现的看法
Because unusual items detracted from Shenzhen Neptunus Interlong Bio-technique's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Because of this, we think Shenzhen Neptunus Interlong Bio-technique's earnings potential is at least as good as it seems, and maybe even better! Unfortunately, though, its earnings per share actually fell back over the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. Our analysis shows 4 warning signs for Shenzhen Neptunus Interlong Bio-technique (1 shouldn't be ignored!) and we strongly recommend you look at them before investing.
由于不寻常的项目削弱了深圳海王英特隆生物技术公司去年的收益,你可以争辩说,我们可以预期本季度的业绩会有所改善。正因为如此,我们认为深圳海王英特隆生物技术的盈利潜力至少和看起来一样好,甚至可能更好!但不幸的是,其每股收益实际上在去年有所回落。当然,我们只是在分析其收益时才浮出水面;人们还可以考虑利润率、预测增长和投资回报率等因素。有鉴于此,如果你想对公司进行更多分析,了解所涉及的风险至关重要。我们的分析显示,深圳海王英特隆生物技术有4个警告信号(其中一个不容忽视!)我们强烈建议您在投资之前先看看它们。
Today we've zoomed in on a single data point to better understand the nature of Shenzhen Neptunus Interlong Bio-technique's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.
今天,我们放大了单个数据点,以更好地了解深圳海王英特隆生物技术有限公司利润的性质。但是,如果你能够将注意力集中在细节上,总会有更多的事情需要发现。有些人认为高股本回报率是优质业务的好兆头。因此,你可能希望看到这份免费收藏的拥有高股本回报率的公司,或者这份内部人士正在购买的股票清单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。